OraSure Technologies (OSUR) vs Profound Medical (PROF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OraSure Technologies (OSUR) has outperformed Profound Medical (PROF) over the past year, gaining 52.4% versus a gain of 6.2%. Over five years, PROF leads with a -43.6% price change compared with -63.7% for OSUR. OraSure Technologies is the larger company by market cap ($238.9 million vs $233.7 million), about 1.0 times the size, while Profound Medical is growing revenue faster (+50.7% vs -38.1%).
OraSure Technologies converts more of its revenue into profit, with a net margin of -59.8% versus -264.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSUR | PROF |
|---|---|---|
| Share price | $3.46 | $6.38 |
| Market cap | $238.90M | $233.68M |
| 1-day change | -4.16% | -3.19% |
| YTD return | +42.98% | -18.93% |
| 1-year return | +52.42% | +6.16% |
| 5-year return | -63.69% | -43.64% |
| EPS (TTM) | $-0.69 | $-0.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $115.02M | $16.10M |
| Revenue growth (YoY) | -38.10% | +50.73% |
| Net income (latest FY) | $-68.73M | $-42.57M |
| Gross margin | 41.90% | 70.77% |
| Operating margin | -62.57% | -256.27% |
| Net margin | -59.76% | -264.44% |
| 52-week high | $4.58 | $8.95 |
| 52-week low | $2.28 | $4.80 |
| Distance from 52-week high | -24.45% | -28.72% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +58.96% | +74.61% |
| Average volume | 571.50K | 208.29K |
| Shares outstanding | 69.05M | 36.63M |
| Employees | 500 | 162 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSUR has outperformed PROF by 46.3 percentage points over the past year.
- OraSure Technologies is more profitable, keeping -59.8 cents of every revenue dollar as net income versus -264.4 cents for Profound Medical.
- Profound Medical grew revenue faster in its latest fiscal year (+50.73% vs -38.10%).
About OraSure Technologies
OSUR stock →OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Health Care · Medical/Dental Instruments · 500 employees
About Profound Medical
PROF stock →Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.
Health Care · Medical/Dental Instruments · 162 employees
OSUR vs PROF FAQ
Which is bigger, OraSure Technologies or Profound Medical?
OraSure Technologies (OSUR) is larger, with a market capitalization of $238.90M compared with $233.68M for Profound Medical (PROF).
Which stock has performed better over the past year, OSUR or PROF?
OSUR returned +52.42% over the past 12 months, compared with +6.16% for PROF (price return, excluding dividends). Past performance does not predict future results.
Are OraSure Technologies and Profound Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.